Маркеры повреждения миокарда на этапах полихимиотерапии у детей с острым лимфобластным лейкозом
Теплякова Елена Дмитриевна · Medical Almanac · 2012
The development of cardiovascular complications is one of the serious negative consequences of polychemotherapy and toxic-infectious processes of children with acute leukemia. They occur at different stages of therapy and in difficult cases can lead to the development of the progressive myocardial dysfunction and heart failure. Nowadays biological markers are widely used in cardiology for the diagnostics of myocardial injury and its function, and also for the evaluation of the prognosis of the disease and its complications. Cardiac troponin I is not a marker of myocardial damage in children with developing cardiovascular complications during chemotherapy. Fatty acid binding protein must be a more specific marker of the developing decrease myocardial contractility in patients with acute lymphoblastic leukemia.
Cited by 0 works.